Anti-HPD / 4HPPD / 4-hydroxyphenylpyruvate dioxygenase

0.5mg/ml if reconstituted with 0.2ml sterile DI water. HPD (4-hydroxyphenylpyruvate dioxygenase) is a key enzyme in the catabolism of the amino acid tyrosine. It catalyzes the conversion of 4-hydroxyphenylpyruvate to homogentisate, an essential step in the tyrosine degradation pathway. By facilitating this reaction, HPD plays an important role in energy metabolism and the production of downstream metabolites. A HPD antibody is widely used in studies of amino acid metabolism and inherited metabolic disorders. HPD is highly expressed in the liver and kidneys, organs that are central to amino acid catabolism. Its activity ensures that tyrosine is efficiently broken down, preventing the accumulation of toxic intermediates. Mutations in the HPD gene are associated with tyrosinemia type III, a rare metabolic disorder characterized by elevated levels of tyrosine in the blood and neurological symptoms. Researchers employ a HPD antibody to investigate enzyme function, tissue distribution, and the molecular basis of metabolic diseases. Beyond its role in metabolism, HPD has clinical importance as a therapeutic target. Small-molecule inhibitors of HPD are being explored to reduce toxic metabolite accumulation in tyrosinemia type I, where blocking this enzyme helps redirect metabolic flux. Using a HPD antibody supports translational research into such therapies by enabling detailed study of enzyme expression and regulation. NSJ Bioreagents offers a high-quality HPD antibody validated for applications such as western blot, immunohistochemistry, and immunofluorescence. Choosing a HPD antibody from NSJ Bioreagents ensures accurate detection and reproducibility in studies of amino acid metabolism, metabolic disorders, and therapeutic development.